Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Derm CasesDermatology / Skin cancer prevention

Derm Cases · Dermatology / Skin cancer prevention

OSCE — rough sun-damaged patches: actinic keratosis field care and SCC red flags

An 8-minute OSCE station on actinic keratosis recognition, field cancerization concepts, lesion- vs field-directed therapy, and when to biopsy for invasive SCC.

8 minosce2 min readVerification in progress

Target exams

NEET-PGINICETUSMLEPLABMRCP
On this page
Study tools

Target exams

NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE station on actinic keratosis recognition, field cancerization concepts, lesion- vs field-directed therapy, and when to biopsy for invasive SCC.

Brief (to candidate)

A 71-year-old fair-skinned man has multiple rough, gritty, erythematous scaly patches on the bald scalp and dorsal forearms that are “easier to feel than see.” One scalp plaque has thickened and become tender over 6 weeks. He has cumulative outdoor sun exposure. You have 8 minutes to diagnose, stratify field disease, plan treatment, and recognise SCC red flags.

Candidate instructions

  1. Recognise actinic keratosis (AK) and place it on the AK → Bowen → invasive SCC spectrum.
  2. Explain field cancerization and why multiple lesions matter.
  3. Distinguish lesion-directed vs field-directed therapy options.
  4. Identify red flags requiring biopsy (thickening, ulceration, pain, treatment failure).
  5. Mention photoprotection and optional chemoprevention concepts (e.g. nicotinamide evidence).
  6. Safety-net for actinic cheilitis / cutaneous horn.
[3]

Examiner checklist (mark each domain / 10)

DomainKey actions expected
RecognitionRough gritty erythematous scale on chronically UV-damaged skin; classic “felt more than seen” AK morphology; spectrum with SCC in situ and invasive SCC[6]
Field conceptExplains field cancerization — contiguous UV-mutated epidermis harbours multiple clinical and subclinical AKs; treating single lesions alone may leave residual field risk[1]
Lesion-directed therapyCryotherapy / curettage / excision for discrete lesions; discuss expected crusting and hypopigmentation risks after cryotherapy[2][3]
Field-directed therapyTopical 5-FU, imiquimod, diclofenac, or PDT for multiple lesions / field disease; set expectations for inflammatory reaction and adherence[2][3][5]
Red flags / biopsyThickening, induration, pain, ulceration, bleeding, cutaneous horn base, or failure of standard therapy → biopsy to exclude invasive SCC; actinic cheilitis has higher malignant potential on the lip[6]
Prevention / counselPhotoprotection; whole-skin surveillance; may mention oral nicotinamide trial evidence for skin-cancer chemoprevention in high-risk patients (specialist context)[4]
CommunicationClear safety-net: return urgently if a plaque hardens, ulcerates, or fails treatment

Model key actions

  • Diagnose multiple AKs with field cancerization and treat both individual lesions and the field.[1][2]
  • Escalate the tender thickened scalp plaque for biopsy rather than further blind cryotherapy.[6]
  • Photoprotection, surveillance, and realistic expectations of field therapy inflammation.[3]

Common errors

  • Calling all scaly sun spots “dry skin” without considering AK.
  • Cryotherapy only while ignoring field therapy for dozens of lesions.
  • Observing a thickening/tender AK without biopsy for invasive SCC.
  • Missing actinic cheilitis risk on the lower lip.
  • Overpromising “cure forever” without follow-up for new AKs/SCC.
[1] [2] [6]
References6ShowHide
  1. [1]Willenbrink TJ, Ruiz ES, Cornejo CM, et al. Field cancerization: Definition, epidemiology, risk factors, and outcomes. Journal of the American Academy of Dermatology, 2020.PMID 32387665
  2. [2]Dianzani C, Conforti C, Giuffrida R, et al. Current therapies for actinic keratosis. International Journal of Dermatology, 2020.PMID 32012240
  3. [3]Worley B, Harikumar V, Reynolds K, et al. Treatment of actinic keratosis: a systematic review. Archives of dermatological research, 2023.PMID 36454335
  4. [4]Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. The New England journal of medicine, 2015.PMID 26488693
  5. [5]Wang JY, Zeitouni N, Austin E, et al. Photodynamic therapy: Clinical applications in dermatology. Journal of the American Academy of Dermatology, 2026.PMID 39986392
  6. [6]Ferrándiz C, Malvehy J, Guillén C, et al. Precancerous Skin Lesions. Actas dermo-sifiliograficas, 2017.PMID 27658688
PreviousOSCE — returned traveller with a volcano ulcer: cutaneous leishmaniasis work-up and when to treat systemicallyDermatology / Infectious disease / Tropical medicineNextOSCE — safe local anaesthesia for office skin surgeryDermatology / Procedural safety